Literature DB >> 15976963

Evaluation of coronary artery patency using cardiac markers.

Milenko J Tanasijevic1.   

Abstract

The availability of a reliable marker of infarct-related artery (IRA) patency status may permit early identification of patients with patent IRA, for whom repeat thrombolysis or rescue percutaneous coronary intervention (PCI) may not be necessary. We found that the ratio of serum myoglobin levels obtained before and 60-min after initiation of thrombolytic therapy provides a useful indication of the IRA patency status. When the 60-min myoglobin ratio was >4.0, the probability of a patent IRA was 90%, suggesting that emergency coronary angiography to determine their IRA status may be unnecessary when this pattern of release of myoglobin is observed. The low specificity of this marker could be addressed by its combined use with other noninvasive tests such as ST-segment resolution and the persistence of chest pain at the time of angiography.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15976963     DOI: 10.1007/s11239-005-0936-2

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  27 in total

1.  Assessment of coronary artery patency after thrombolytic therapy: accurate prediction utilizing the combined analysis of three noninvasive markers.

Authors:  S H Hohnloser; M Zabel; W Kasper; T Meinertz; H Just
Journal:  J Am Coll Cardiol       Date:  1991-07       Impact factor: 24.094

2.  Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy.

Authors:  J A de Lemos; D A Morrow; C M Gibson; S A Murphy; N Rifai; M Tanasijevic; R P Giugliano; K C Schuhwerk; C H McCabe; C P Cannon; E M Antman; E Braunwald
Journal:  Am J Cardiol       Date:  2001-08-15       Impact factor: 2.778

3.  Patterns of myoglobin release after reperfusion of injured myocardium.

Authors:  A K Ellis; T Little; A R Zaki Masud; F J Klocke
Journal:  Circulation       Date:  1985-09       Impact factor: 29.690

4.  Noninvasive detection of reperfusion after thrombolysis based on serum creatine kinase MB changes and clinical variables. TAMI 7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction.

Authors:  E M Ohman; R H Christenson; R M Califf; B S George; J K Samaha; D J Kereiakes; S J Worley; T C Wall; E Berrios; K N Sigmon
Journal:  Am Heart J       Date:  1993-10       Impact factor: 4.749

5.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

6.  Creatine kinase MM and MB isoforms in patients receiving thrombolytic therapy and acute angiography. TAMI Study Group.

Authors:  R H Christenson; E M Ohman; E J Topol; M A O'Hanesian; K N Sigmon; S H Duh; D Kereiakes; S J Worley; B S George; C K Pizzo
Journal:  Clin Chem       Date:  1995-06       Impact factor: 8.327

7.  Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction.

Authors:  H A Katus; A Remppis; T Scheffold; K W Diederich; W Kuebler
Journal:  Am J Cardiol       Date:  1991-06-15       Impact factor: 2.778

8.  Assessment of reperfusion of the infarct zone after acute myocardial infarction by serial cardiac troponin T measurements in serum.

Authors:  A Remppis; T Scheffold; O Karrer; J Zehelein; C Hamm; E Grünig; C Bode; W Kübler; H A Katus
Journal:  Br Heart J       Date:  1994-03

9.  Non-invasive assessment of infarct reperfusion: the predictive power of the time to peak value of myoglobin, CKMB, and CK in serum.

Authors:  H A Katus; K W Diederich; T Scheffold; M Uellner; F Schwarz; W Kübler
Journal:  Eur Heart J       Date:  1988-06       Impact factor: 29.983

10.  Usefulness of a rapid initial increase in plasma creatine kinase activity as a marker of reperfusion during thrombolytic therapy for acute myocardial infarction.

Authors:  B S Lewis; W Ganz; P Laramee; B Cercek; H Hod; P K Shah; A S Lew
Journal:  Am J Cardiol       Date:  1988-07-01       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.